Literature DB >> 32352361

Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists.

Hèctor Corominas1, Ivan Castellví1, Pere Domingo2, Jordi Casademont3.   

Abstract

Entities:  

Year:  2020        PMID： 32352361      PMCID： PMC7431335          DOI： 10.5152/eurjrheum.2020.20061

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN： 2147-9720


× No keyword cloud information.
  16 in total

1.  Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.

Authors:  Jin-Jin Zhang; Xiang Dong; Yi-Yuan Cao; Ya-Dong Yuan; Yi-Bin Yang; You-Qin Yan; Cezmi A Akdis; Ya-Dong Gao
Journal:  Allergy       Date:  2020-02-27       Impact factor: 13.146

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

3.  Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.

Authors:  Andre C Kalil
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

4.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome.

Authors:  Yaseen M Arabi; Yasser Mandourah; Fahad Al-Hameed; Anees A Sindi; Ghaleb A Almekhlafi; Mohamed A Hussein; Jesna Jose; Ruxandra Pinto; Awad Al-Omari; Ayman Kharaba; Abdullah Almotairi; Kasim Al Khatib; Basem Alraddadi; Sarah Shalhoub; Ahmed Abdulmomen; Ismael Qushmaq; Ahmed Mady; Othman Solaiman; Abdulsalam M Al-Aithan; Rajaa Al-Raddadi; Ahmed Ragab; Hanan H Balkhy; Abdulrahman Al Harthy; Ahmad M Deeb; Hanan Al Mutairi; Abdulaziz Al-Dawood; Laura Merson; Frederick G Hayden; Robert A Fowler
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Authors:  Qiurong Ruan; Kun Yang; Wenxia Wang; Lingyu Jiang; Jianxin Song
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

Review 8.  Potential therapeutic agents against COVID-19: What we know so far.

Authors:  Chih-Chia Lu; Mei-Yu Chen; Wan-Shin Lee; Yuh-Lih Chang
Journal:  J Chin Med Assoc       Date:  2020-06       Impact factor: 2.743

9.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

Authors:  Clark D Russell; Jonathan E Millar; J Kenneth Baillie
Journal:  Lancet       Date:  2020-02-07       Impact factor: 79.321

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321
View more
  3 in total

1.  Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.

Authors:  Hèctor Corominas; Ivan Castellví; César Diaz-Torné; Laia Matas; David de la Rosa; Maria Antònia Mangues; Patricia Moya; Virginia Pomar; Natividad Benito; Ester Moga; Nerea Hernandez-de Sosa; Jordi Casademont; Pere Domingo
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

2.  COVID-19: Overview of Rheumatology Fellows.

Authors:  Andrea Garcia-Guillén; Sicylle Jeria; David Lobo-Prat; Luís Sainz
Journal:  Reumatol Clin (Engl Ed)       Date:  2020-06-11

3.  Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

Authors:  Hèctor Corominas; Ivan Castellví; Virginia Pomar; Rosa Antonijoan; Isabel Mur; Laia Matas; Ignasi Gich; Natividad de Benito; Ana Laiz; Diego Castillo; Laura Villamarin; David Filella; Ana Milena Millán; María Ángeles Quijada; Mireia Puig; Jordi Casademont; Pere Domingo
Journal:  Clin Immunol       Date:  2020-11-12       Impact factor: 3.969
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.